Literature DB >> 33082526

The clinical significance of A2ML1 variants in Noonan syndrome has to be reconsidered.

Julia Brinkmann1, Christina Lissewski1, Valentina Pinna2, Yoann Vial3,4, Francesca Pantaleoni5, Francesca Lepri5, Paola Daniele2, Birute Burnyte6, Goran Cuturilo7,8, Christine Fauth9, Alper Gezdirici10, Dieter Kotzot9, Elif Yılmaz Güleç10, Violeta Iotova11, Denny Schanze1, Francis Ramond12, Markéta Havlovicová13, Gulen Eda Utine14, Pelin Ozlem Simsek-Kiper14, Milena Stoyanova15, Alain Verloes3, Alessandro De Luca2, Marco Tartaglia5, Hélène Cavé3,4, Martin Zenker16.   

Abstract

The RASopathies are a group of clinically and genetically heterogeneous developmental disorders caused by dysregulation of the RAS/MAPK signalling pathway. Variants in several components and regulators of this pathway have been identified as the pathogenetic cause. In 2015, missense variants in A2ML1 were reported in three unrelated families with clinical diagnosis of Noonan syndrome (NS) and a zebrafish model was presented showing heart and craniofacial defects similar to those caused by a NS-associated Shp2 variant. However, a causal role of A2ML1 variants in NS has not been confirmed since. Herein, we report on 15 individuals who underwent screening of RASopathy-associated genes and were found to carry rare variants in A2ML1, including variants previously proposed to be causative for NS. In cases where parental DNA was available, the respective A2ML1 variant was found to be inherited from an unaffected parent. Seven index patients carrying an A2ML1 variant presented with an alternate disease-causing genetic aberration. These findings underscore that current evidence is insufficient to support a causal relation between variants in A2ML1 and NS, questioning the inclusion of A2ML1 screening in diagnostic RASopathy testing.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33082526      PMCID: PMC7940614          DOI: 10.1038/s41431-020-00743-3

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  4 in total

1.  Molecular and clinical profile of patients referred as Noonan or Noonan-like syndrome in Greece: a cohort of 86 patients.

Authors:  George Papadopoulos; Anna Papadopoulou; Konstantina Kosma; Anastasios Papadimitriou; Vassiliki Papaevangelou; Christina Kanaka-Gantenbein; Evangelia Bountouvi; Sophia Kitsiou-Tzeli
Journal:  Eur J Pediatr       Date:  2022-07-29       Impact factor: 3.860

Review 2.  The RASopathies: from pathogenetics to therapeutics.

Authors:  Katie E Hebron; Edjay Ralph Hernandez; Marielle E Yohe
Journal:  Dis Model Mech       Date:  2022-02-18       Impact factor: 5.758

3.  Cognitive Phenotype and Psychopathology in Noonan Syndrome Spectrum Disorders through Various Ras/MAPK Pathway Associated Gene Variants.

Authors:  Ellen Wingbermühle; Renée L Roelofs; Wouter Oomens; Jennifer Kramer; Jos M T Draaisma; Erika Leenders; Tjitske Kleefstra; Roy P C Kessels; Jos I M Egger
Journal:  J Clin Med       Date:  2022-08-13       Impact factor: 4.964

Review 4.  Etiology and Treatment of Growth Delay in Noonan Syndrome.

Authors:  Fernando Rodríguez; Ximena Gaete; Fernando Cassorla
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-04       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.